- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Turn Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Turn Therapeutics: Positive Studiendaten zu Ekzem-Medikament treiben Aktie an | 3 | Investing.com Deutsch | ||
| 01.06. | Turn Therapeutics reports interim phase 2 data for eczema drug | 2 | Investing.com | ||
| 27.05. | Turn Therapeutics publishes GX-03 dermatitis study results | 1 | Investing.com | ||
| 27.05. | Turn Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Turn Therapeutics Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| TURN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.05. | Turn Therapeutics appoints former FDA chief Stephen Hahn | 3 | Investing.com | ||
| 11.05. | Turn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Turn Therapeutics Inc. GAAP EPS of -$0.12 beats by $0.01 | 3 | Seeking Alpha | ||
| 31.03. | Turn Therapeutics Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Turn Therapeutics: $25 Million Financing Secured By Dermatology Biotechnology Company | 3 | pulse2.com | ||
| 24.03. | Turn Therapeutics secures up to $25M in financing from Avenue Capital Group | 1 | Seeking Alpha | ||
| 24.03. | Turn Therapeutics secures $25M loan facility from Avenue Capital | 1 | Investing.com | ||
| 24.03. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Turn Therapeutics erhält Kreditfazilität von bis zu 25 Millionen US-Dollar von Avenue Capital | 3 | Investing.com Deutsch | ||
| 17.02. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.02. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TILRAY BRANDS | 3,900 | +1,69 % | Tilray-Aktie: Startet jetzt die 700%-Chance? | Die Tilray-Aktie hat in den vergangenen Tagen eine bemerkenswerte Kehrtwende vollzogen. Nach enttäuschenden Quartalszahlen am 28. Juli geriet der Cannabis-Titel zunächst unter Druck, ehe bereits einen... ► Artikel lesen | |
| VIATRIS | 14,178 | -7,14 % | Viatris Posts Wider Loss In Q2; Raises 2026 Guidance | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) reported a second-quarter net loss of $118.8 million compared to a net loss of $4.6 million, a year ago. GAAP diluted loss per share was $0.10 compared... ► Artikel lesen | |
| SYNBIOTIC | 1,140 | +3,83 % | EQS-Adhoc: SYNBIOTIC SE: SOLIDMIND Group GmbH und Lean Labs Pharma GmbH beabsichtigen, Anträge auf Eröffnung von Insolvenzverfahren zu stellen | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Strategische Unternehmensentscheidung/Insolvenz
SYNBIOTIC SE: SOLIDMIND Group GmbH und Lean Labs Pharma GmbH beabsichtigen, Anträge auf Eröffnung... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 9,910 | +1,79 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. | ||
| SELLAS LIFE SCIENCES | 10,150 | -1,46 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,814 | -3,69 % | XORTX Therapeutics Inc.: XORTX Announces Director Resignation | CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| SOLIGENIX | 0,379 | -1,12 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| TALPHERA | 1,140 | -1,72 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,961 | +5,11 % | Savara Inc.: Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | -- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI's Proprietary eFlow Nebulizer System... ► Artikel lesen | |
| SCYNEXIS | 5,220 | 0,00 % | Brookline bestätigt Kursziel für Scynexis von 44,64 USD und sieht massives Aufwärtspotenzial | ||
| THERIVA BIOLOGICS | 0,222 | -1,38 % | Theriva Biologics, Inc.: Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma | - VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) -
-... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 5,250 | +1,94 % | Wave Life Sciences redomiciliation to U.S. set for Friday | ||
| TUHURA BIOSCIENCES | 1,870 | +2,75 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers | The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination... ► Artikel lesen | |
| THERAPEUTICSMD | 1,720 | +1,18 % | TherapeuticsMD, Inc. - 8-K, Current Report | ||
| YARROW BIOSCIENCE | 41,635 | +10,44 % | Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves Disease and Thyroid Eye Disease | Yarrow is advancing YB-101-a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves' disease ("GD") and thyroid eye disease ("TED")
Dosing... ► Artikel lesen |
TURN THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,180 (+1,91 %) liegt der Kurs bei 9,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURN THERAPEUTICS INC finden Sie auf Wallstreet Online.